Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development and translational research gained in leading industry and academic institutions. In his role as Chief Medical Officer, he will be responsible for clinical development activities as well as regulatory affairs. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares after opening at $26.58 on last trade day and at the end of the day closed at $25.21. Company price to sales ratio in past twelve months was calculated as 71.07 and price to cash ratio as 8.19. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) showed a negative weekly performance of -21.71%.
On March 27, Spherix Inc (NASDAQ:SPEX), which buys and licenses technology patents, said it filed a lawsuit against Cisco Inc alleging infringement of 11 patents Spherix acquired from Nortel Networks. Spherix Inc (NASDAQ:SPEX) shares fell -4.98% in last trading session and ended the day on $2.86. SPEX return on equity ratio is recorded as -550.40% and its return on assets is -373.10%. Spherix Inc (NASDAQ:SPEX) yearly performance is -59.60 %.
Wedbush initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $10.00 price target on the stock. Wedbush’s price objective suggests a potential downside of 32.02% from the company’s current price. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved down -2.50% in last trading session and was closed at $11.30, while trading in range of $10.90 – $11.80. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date (YTD) performance is -18.18%.
On Feb. 12, 2014, Ventrus Biosciences Inc (NASDAQ:VTUS) announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 7.09 for diltiazem 2% and 7.18 for placebo, decreasing to 3.81 (-3.28 difference) and 3.72 (-3.46 difference) respectively. Outcomes for the secondary endpoints of overall AF-related pain and PGI-I parallel the primary endpoint. Age, gender, and race were equivalent between arms, and results were not meaningfully different between countries. Ventrus Biosciences Inc (NASDAQ:VTUS) weekly performance is -7.52%. On last trading day company shares ended up $1.23. Ventrus Biosciences Inc (NASDAQ:VTUS) distance from 50-day simple moving average (SMA50) is -45.79%. Analysts mean target price for the company is $2.50.